Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The user has been on finasteride for 8 months and minoxidil for 3 months, experiencing minor regrowth at the temples but overall worse hair loss, with constant shedding and itching. They are concerned about thinning on the sides and nape, questioning if it's diffuse unpatterned alopecia (DUPA) and seeking advice on what to do next.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

A user is considering starting treatments like Finasteride, Minoxidil, and Microneedling for hair thinning, despite stable hair loss for over 8 years. They are unsure if the presence of miniaturized hairs indicates potential for regrowth or if they should accept the current state.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.

An 18-year-old is concerned about potential balding and seeks advice. They are unsure if their hairline is a widow's peak or if they are experiencing hair loss.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A 24-year-old experienced significant hair regrowth over 8 months using oral finasteride, oral and topical minoxidil, dutasteride, microneedling, and ketoconazole shampoo. They are satisfied with the results and may consider a hair transplant after one year.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A 25-year-old who started losing hair at 16 and reached almost NW7 by 20 saw hair regrowth using a regimen including dutasteride, minoxidil, nizoral, and a dermaroller, along with supplements like biotin, zinc, and omega-3. After initial success, they experienced shedding, added more supplements and treatments, and sought advice on whether to continue; responses encouraged them to persist as shedding is often part of the hair regrowth cycle.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

A 20-year-old is experiencing hair thinning due to vitamin D deficiency and has completed a vitamin D prescription without seeing improvement. Suggestions include waiting a few months for potential regrowth or considering treatments like minoxidil or finasteride for androgenetic alopecia.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

A 20-year-old male experienced bald spots and used minoxidil, which led to hair regrowth but also premature graying. He seeks advice on reversing graying through diet or supplements like catalase, while another user suggests vitamin D3 and sesame for hair color.

A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.

Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.

A 31-year-old male considering returning to finasteride at a lower dose or using topical finasteride to assess his Norwood scale for a potential future hair transplant. He previously stopped finasteride due to side effects and has been shaving his head.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.